Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients

Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients

  • نوع فایل : کتاب
  • زبان : انگلیسی
  • مؤلف : Denis Lane (denis.lane@usherbrooke.ca) Isabelle Matte (isabelle.matte@usherbrooke.ca) Claudine Rancourt (claudine.rancourt@usherbrooke.ca) Alain Pi
  • چاپ و سال / کشور: 2011

Description

Background – The acellular fraction of epithelial ovarian cancer (EOC) ascites promotes de novo resistance of tumor cells and thus supports the idea that tumor cells may survive in the surrounding protective microenvironment contributing to disease recurrence. Levels of the proinflammatory cytokines IL-6 and IL-8 are elevated in EOC ascites suggesting that they could play a role in tumor progression. Methods – We measured IL-6 and IL-8 levels in the ascites of 39 patients with newly diagnosed EOC. Commercially available enzyme-linked immunosorbent assay (ELISA) was used to determine IL-6 and IL-8 ascites levels. Ascites cytokine levels were correlated with clinicopathological parameters and progression-free survival. Results - Mean ascites levels for IL-6 and IL-8 were 6419 pg/ml (SEM: 1409 pg/ml) and 1408 pg/ml (SEM: 437 pg/ml) respectively. The levels of IL-6 and IL-8 in ascites were significantly lower in patients that have received prior chemotherapy before the surgery (Mann-Whitney U test, P = 0.037 for IL-6 and P = 0.008 for IL-8). Univariate analysis revealed that high IL-6 ascites levels (P = 0.021), serum CA125 levels (P = 0.04) and stage IV (P = 0.009) were significantly correlated with shorter progression-free survival. Including these variables in a multivariate analysis revealed that elevated IL-6 levels (P = 0.033) was an independent predictor of shorter progression-free survival. Conclusion – Elevated IL-6, but not IL-8, ascites level is an independent predictor of shorter progression-free survival.
BMC Cancer 2011, 11:210 doi:10.1186/1471-2407-11-210 ISSN 1471-2407 Article type Research article Submission date 17 March 2011 Acceptance date 30 May 2011 Publication date 30 May 2011
اگر شما نسبت به این اثر یا عنوان محق هستید، لطفا از طریق "بخش تماس با ما" با ما تماس بگیرید و برای اطلاعات بیشتر، صفحه قوانین و مقررات را مطالعه نمایید.

دیدگاه کاربران


لطفا در این قسمت فقط نظر شخصی در مورد این عنوان را وارد نمایید و در صورتیکه مشکلی با دانلود یا استفاده از این فایل دارید در صفحه کاربری تیکت ثبت کنید.

بارگزاری